Ursula A. Matulonis

Ursula Matulonis is a leading gynecologic oncologist who has led transformative clinical trials in ovarian cancer, particularly in the platinum-resistant setting where treatment options remain limited. She was a principal investigator of the SORAYA and MIRASOL trials establishing mirvetuximab soravtansine as the first ADC approved for platinum-resistant ovarian cancer with high FRalpha expression. Matulonis has led studies of PARP inhibitors in BRCA-mutated ovarian cancer and has driven development of novel immune and antibody-based approaches for this difficult-to-treat malignancy. She co-chairs multiple NCI cooperative group trials in gynecologic oncology.